With the new analysis, researchers rule out embolic protection for stroke prevention in TAVI, but not everybody has given up.

Researchers say the data underscore the need for more aggressive surveillance of patients, even when AS is moderate AS.

Looking toward approval in the US, larger studies with careful hemodynamic data will be needed, says Martin Leon.

The observed treatment rates, which “absolutely can go higher,” wouldn’t be acceptable for serious cancers, Stephen Greene ...

These exploratory results from the FINEARTS-HF trial require confirmation in dedicated trials. REDEFINE-HF is underway.